AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts)

C. Cardone; B. Blauensteiner; V. Moreno-Viedma; M. C. Paul; G. Martini; P. P. Vitiello; D. Ciardiello; C. Borrelli; L. Poliero; P. Vitale; N. Zanaletti; V. Famiglietti; A. M. Rachiglio; D. Rizzi; E. Maiello; T. P. Latiano; N. Normanno; M. Sibilia; F. Ciardiello; E. Martinelli

doi:10.1093/annonc/mdy269.094

AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts)

C. Cardone, B. Blauensteiner, V. Moreno-Viedma, M. C. Paul, G. Martini, P. P. Vitiello, D. Ciardiello, C. Borrelli, L. Poliero, P. Vitale, N. Zanaletti, V. Famiglietti, A. M. Rachiglio, D. Rizzi, E. Maiello, T. P. Latiano, N. Normanno, M. Sibilia, F. Ciardiello, E. Martinelli

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	viii30
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy269.094
Publication status	Published - Oct 1 2018

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdy269.094

Cite this

Cardone, C., Blauensteiner, B., Moreno-Viedma, V., Paul, M. C., Martini, G., Vitiello, P. P., Ciardiello, D., Borrelli, C., Poliero, L., Vitale, P., Zanaletti, N., Famiglietti, V., Rachiglio, A. M., Rizzi, D., Maiello, E., Latiano, T. P., Normanno, N., Sibilia, M., Ciardiello, F., & Martinelli, E. (2018). AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts). Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii30. https://doi.org/10.1093/annonc/mdy269.094

AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts). / Cardone, C.; Blauensteiner, B.; Moreno-Viedma, V.; Paul, M. C.; Martini, G.; Vitiello, P. P.; Ciardiello, D.; Borrelli, C.; Poliero, L.; Vitale, P.; Zanaletti, N.; Famiglietti, V.; Rachiglio, A. M.; Rizzi, D.; Maiello, E.; Latiano, T. P.; Normanno, N.; Sibilia, M.; Ciardiello, F.; Martinelli, E.

In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.10.2018, p. viii30.

Research output: Contribution to journal › Article › peer-review

Cardone, C, Blauensteiner, B, Moreno-Viedma, V, Paul, MC, Martini, G, Vitiello, PP, Ciardiello, D, Borrelli, C, Poliero, L, Vitale, P, Zanaletti, N, Famiglietti, V, Rachiglio, AM, Rizzi, D, Maiello, E , Latiano, TP , Normanno, N , Sibilia, M, Ciardiello, F & Martinelli, E 2018, 'AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts)', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii30. https://doi.org/10.1093/annonc/mdy269.094

Cardone C, Blauensteiner B, Moreno-Viedma V, Paul MC, Martini G, Vitiello PP et al. AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts). Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1;29:viii30. https://doi.org/10.1093/annonc/mdy269.094

Cardone, C. ; Blauensteiner, B. ; Moreno-Viedma, V. ; Paul, M. C. ; Martini, G. ; Vitiello, P. P. ; Ciardiello, D. ; Borrelli, C. ; Poliero, L. ; Vitale, P. ; Zanaletti, N. ; Famiglietti, V. ; Rachiglio, A. M. ; Rizzi, D. ; Maiello, E. ; Latiano, T. P. ; Normanno, N. ; Sibilia, M. ; Ciardiello, F. ; Martinelli, E. / AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts). In: Annals of oncology : official journal of the European Society for Medical Oncology. 2018 ; Vol. 29. pp. viii30.

@article{0b04a52c02724b609a70664acf94b8e6,

title = "AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts)",

author = "C. Cardone and B. Blauensteiner and V. Moreno-Viedma and Paul, {M. C.} and G. Martini and Vitiello, {P. P.} and D. Ciardiello and C. Borrelli and L. Poliero and P. Vitale and N. Zanaletti and V. Famiglietti and Rachiglio, {A. M.} and D. Rizzi and E. Maiello and Latiano, {T. P.} and N. Normanno and M. Sibilia and F. Ciardiello and E. Martinelli",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy269.094",

language = "English",

volume = "29",

pages = "viii30",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "NLM (Medline)",

}

TY - JOUR

T1 - AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts)

AU - Cardone, C.

AU - Blauensteiner, B.

AU - Moreno-Viedma, V.

AU - Paul, M. C.

AU - Martini, G.

AU - Vitiello, P. P.

AU - Ciardiello, D.

AU - Borrelli, C.

AU - Poliero, L.

AU - Vitale, P.

AU - Zanaletti, N.

AU - Famiglietti, V.

AU - Rachiglio, A. M.

AU - Rizzi, D.

AU - Maiello, E.

AU - Latiano, T. P.

AU - Normanno, N.

AU - Sibilia, M.

AU - Ciardiello, F.

AU - Martinelli, E.

PY - 2018/10/1

Y1 - 2018/10/1

UR - http://www.scopus.com/inward/record.url?scp=85077978841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077978841&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy269.094

DO - 10.1093/annonc/mdy269.094

M3 - Article

C2 - 32136697

VL - 29

SP - viii30

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

ER -

AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts)

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this